Based on immunohistochemical analysis in 58 recurrent and 176 non recurrent PCa patients, TROP2 was identified as highly expressed in recurrent PCa and significantly correlated with biochemical recurrence over a period of nine years (BCR; p < 0.05) [27]. Here, TACSTD2 is linked to posterior cortical atrophy.